Head-to-head evidence
Diazepam (Libervant) vs Ganaxolone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diazepam (Libervant)
Marketed by Aquestive Therapeutics, Inc.
NCT03428360 · Phase 3 · completed
The study treated 130 participants with diazepam buccal film in a single open-label group, without randomization, blinding, or a control arm. Its primary outcomes were safety event counts rather than a controlled clinical comparison, so the findings cannot establish comparative treatment effectiveness.
Ganaxolone
Marketed by Immedica Pharma AB
NCT01963208 · Phase 3 · completed
The primary phase was well controlled, with randomized quadruple blinding, placebo comparison, and 350 analyzed participants, and it used the clinical endpoint of change in seizure frequency. However, the primary endpoint was missed: the difference between ganaxolone and placebo was not statistically significant (p=0.1788), so the study provides well-designed but inconclusive evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Libervant)'s landscape · Ganaxolone's landscape